ValbiotisXPAR:ALVAL -7.22%55 EBITDA Margin % is -800.70% as of Dec. 2025. GuruFocus rates XPAR:ALVAL with a GF Score™ of 55/100 and a GF Value™ of €1.49 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 1,953 Consumer Packaged Goods companies, Valbiotis ranks worse than 99.13% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Valbiotis's EBITDA for the
six
months ended in Dec. 2025 was €-4.59 Mil. Valbiotis's Revenue for the
six
months ended in Dec. 2025 was €0.57 Mil. Therefore, Valbiotis's EBITDA margin for the quarter that ended in Dec. 2025 was -800.70%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Valbiotis EBITDA Margin % Related Terms
Valbiotis EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Valbiotis's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XPAR:ALVAL vs KHC, GIS: EBITDA Margin % Comparison
For the Packaged Foods subindustry, Valbiotis's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Valbiotis EBITDA Margin % vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Valbiotis's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Valbiotis's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Valbiotis (XPAR:ALVAL) has a EBITDA Margin % of -800.70% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Valbiotis and its competitors. According to the industry distribution chart, Valbiotis ranks #1936 out of 1953 companies in the Consumer Packaged Goods industry, placing it in the top 99.1%.
Is Valbiotis' EBITDA Margin % too high?
Valbiotis' current EBITDA Margin % is -800.70%. Based on the distribution chart, Valbiotis ranks #1936 out of 1953 companies in the Consumer Packaged Goods industry, which is in the bottom quartile relative to peers. Overall, Valbiotis has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Valbiotis' EBITDA Margin % compare to KHC and GIS?
According to the Consumer Packaged Goods industry distribution chart, Valbiotis ranks #1936 out of 1953 companies for EBITDA Margin %. This places Valbiotis in the lower half of its industry. The industry median EBITDA Margin % is 8.99. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Consumer Packaged Goods company?
The median EBITDA Margin % among Consumer Packaged Goods companies is 8.99, based on 1,953 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Valbiotis and its competitors. For the Consumer Packaged Goods industry, the median EBITDA Margin % is 8.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Valbiotis's current EBITDA Margin % is -800.70%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Valbiotis stock overvalued right now?
Based on GuruFocus' analysis, Valbiotis (XPAR:ALVAL) is currently considered Possible Value Trap. The stock's GF Value™ is €1.49, compared to a current price of €0.75 — trading 50% below its estimated fair value. The current EBITDA Margin % is -800.70%. Valbiotis' overall GF Score™ is 55/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Valbiotis (XPAR:ALVAL), the current EBITDA Margin % is -800.70% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Valbiotis (XPAR:ALVAL) Overvalued in 2026?
Based on GuruFocus' analysis, Valbiotis stock appears to be undervalued.
The current stock price of €0.75 is trading 50% below its estimated GF Value™ of €1.49.
GuruFocus considers Valbiotis to be Possible Value Trap.
Key valuation signals for XPAR:ALVAL:
EBITDA Margin %: -800.70%
GF Value™: €1.49 vs. price of €0.75 (50% below fair value)
No single metric tells the full story. See the XPAR:ALVAL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Valbiotis SA is a research & development company. It is engaged in scientific innovation for preventing and combating metabolic diseases. Valbiotis has adopted an approach, aiming to revolutionize healthcare by developing a new class of Nutrition Health products designed to reduce the risk of metabolic diseases, based on a multi-target approach by the use of plant-based ingredients.
55GF Score
Get the complete analysis for XPAR:ALVAL
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:ALVAL has been successfully added to your 
